Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
Observations were made in 5 healthy subjects who exercised before and 1, 3, 6, 8 and 24 h after the oral administration on separate occasions of 160 mg oxprenolol, 160 mg slow release oxprenolol, 160 mg long acting propranolol and 400 mg sotalol. Blood samples were obtained before and at 1, 2, 3, 6, 8, 10 and 24 h after drug administration and assayed for drug concentration. Although the plasma concentration of oxprenolol after S.R. oxprenolol was significantly less at 1 and 2 h and significantly greater at 24 h than after conventional oxprenolol, there was little difference between the effects of the two drugs on an exercise tachycardia. The plasma level of propranolol and the reduction in an exercise tachycardia after L.A. propranolol increased slowly to reach a peak at 6 h and then declined gradually to 24 h. The maximum plasma concentration and effect after sotalol occurred at 3 h and then declined with an elimination half-life of 12.1 h. At 24 h the percentage reduction in an exercise tachycardia was 8.3 +/- 2.5 after oxprenolol, 10.0 +/- 2.3 after S.R. oxprenolol, 18.0 +/- 3.2 after L.A. propranolol and 14.7 +/- 3.4% after sotalol.
D000328:Adult; D003692:Delayed-Action Preparations; D005260:Female; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D010096:Oxprenolol / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D005082:Physical Exertion; D011433:Propranolol / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D013015:Sotalol / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D013610:Tachycardia / Q000188:drug therapy; D013997:Time Factors
D003692:Delayed-Action Preparations; D010096:Oxprenolol; D011433:Propranolol; D013015:Sotalol